Join us at booth H7C19
Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial
We are thrilled to announce the publication of a major clinical study conducted at MEDIAN Klinik Flechtingen, showcasing the benefits of ReOxy® for patients with long COVID.
ReOxy® Featured in Newly Published Long-COVID Study
We are thrilled to announce the publication of a major clinical study conducted at MEDIAN Klinik Flechtingen, showcasing the benefits of ReOxy® for patients with long COVID.
AiMediq at the ESC Preventive Cardiology 2024
This year, we are thrilled to join the ESC Preventive Cardiology 2024 in Athens — 25-27 April, booth n°B3.
Unveiling the Benefits of controlled hypoxia
In this article, we delve into the positive effects of intermittent hypoxia and explore the underlying mechanisms driving these benefits.
ESC Congress 2023, Amsterdam
This year, Ai Mediq had the privilege of participating in the European Society of Cardiology (ESC) Congress held in the city of Amsterdam. This prestigious congress brings together experts from private and public institutions worldwide to exchange knowledge and discoveries in the realm of cardiovascular medicine.
Multiple Sclerosis
Ai Mediq S.A. is pleased to announce the new stage of scientific cooperation with the Universitätsklinikum Hamburg-Eppendorf (UKE). Together with Dr. Sina Cathérine Rosenkranz we will be looking into potential perspectives of Interval Hypoxic Therapy in the treatment of multiple sclerosis.
Presentation in Baden-Baden
Presentation of the Intermittent Hypoxic Training Method in one of the well-known Liliane Goschy-FRITZ Institute in Baden-Baden, Germany on the 15th if July 2020.